1. Generics Bulletin
  2. >>Business
  3. >>Deals

Amended Credit Agreement Aids Lannett As It Commits To The US Generics Space 

 
• By Dean Rudge

Saddled with a mountain of debt and the loss of a lucrative distribution contract representing around a third of annual revenues, Lannett is looking to bounce back in 2019. A recently-signed amendment to its credit agreement, providing much-needed financial breathing room, and a stacked pipeline are boons for the US-centric player.  

ManOnChair
With greater financial breathing room secured, Lannett is better positioned to move on opportunities • Source: Shutterstock

“We are pleased to have the support of our lenders and appreciate their confidence in Lannett, due in part to the excellent progress we are making expanding our pipeline and launching new products, while also reducing our costs.” 

So said Lannett’s chief executive Tim Crew as the company announced a further amendment to the credit agreement it entered...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Viatris Signals Ongoing Strategic Overhaul, Promises Update In Q3

 
• By Dean Rudge

Viatris is conducting a company-wide strategic review to boost long-term competitiveness, targeting cost savings and a shift to complex, high-margin products. CEO Scott Smith says it’s timely after four divestitures. An update is due in the Q3 2025 earnings call in November.

Lupin Couples Up With Sandoz For Global Lucentis Biosimilar Deal

 
• By Urtė Fultinavičiūtė

Sandoz snatched commercialization rights to Lupin’s ranibizumab biosimilar across multiple global markets, while also taking steps to decarbonize its operations in Europe.

Hikma Rides Price Gap as Novo’s Ozempic, Wegovy Costs Climb

 
• By Dean Rudge

Hikma is seeing increased US demand for its generic Victoza (liraglutide) after the end of semaglutide compounding lifted prices for Novo Nordisk’s Ozempic and Wegovy. Meanwhile, the company is not for now pursuing semaglutide generics in the US or EU due to patent protection, but is targeting MENA.